Patients with the chronic skin condition hidradenitis suppurativa were less likely to be hospitalized with COVID-19 vs a control group.
Hidradenitis suppurativa (HS) does not appear to be a risk factor for severe COVID-19 infection, according to a new retrospective analysis.
The study, published in Skin Appendage Disorders,1 found no increased risk for complications or the need for COVID-19 treatment among a cohort of patients with the comorbidities compared with a group of patients who had COVID-19 but not HS.
HS is a chronic inflammatory skin disease in which patients develop small, painful subcutaneous nodules in areas like the armpits and inner thighs. The study authors said HS is associated with certain comorbidities that are risk factors for COVID-19 severity. In addition, HS disproportionately affects people of color, with previous research showing that patients of Black, Hispanic, and Native American ethnicity are at a higher risk of severe COVID-19.2
The investigators wanted to know whether HS itself might be an independent risk factor for severe COVID-19. To find out, they retrospectively reviewed the medical records of University of Arkansas for Medical Sciences patients who tested positive for COVID-19 between March 2020 and September 2021. They constructed a cohort of 58 patients with both HS and COVID-19, and compared them with an age-, race-, and sex-matched control group of 63 patients without HS who had COVID-19.
Female patients made up the majority of both the HS group and the control group (88% and 84%, respectively), and most patients in both cohorts were African American (83% and 79%).
The most common comorbidities in the HS group were obesity (72%), cardiovascular disease (24%) and diabetes (19%), the authors found. Those were also the most common comorbidities among the non-HS cohort. However, the non-HS cohort had a significantly higher rate of cardiovascular disease (51%) than the HS cohort, and 12 patients in the non-HS cohort were pregnant (23%) vs 2 patients (4%) in the HS group. Only 1 patient (part of the HS cohort) was taking a biologic.
More than half of the patients in each cohort received their COVID-19 diagnosis prior to the wide availability of vaccines against the infection, the authors noted. As a result, a minority of patients were vaccinated at the time of diagnosis (6% in the HS-positive group and 5% in the HS-negative group). Rates of vaccination had increased significantly by the time of data collection, the authors said.
When the investigators looked at COVID-19 outcomes, they found the non-HS group had more severe outcomes. Thirty-five percent of patients in the control group experienced COVID-19 complications vs just 7% in the HS group. Nearly one-third of patients in the control group were hospitalized with COVID-19 (32%), but only 2 patients in the HS group required hospitalization. Patients in the control group were also more likely to need oxygen supplementation (30% vs 3%) or receive treatment for COVID-19 (37% vs 7%).
“Despite similar rates of most comorbidities and vaccination rates, HS+/COVID+ patients had significantly better COVID-19 outcomes compared to HS−/COVID+ patients,” the study authors wrote.
The findings suggest HS does not confer a greater risk for severe COVID-19, the authors said, although they cautioned that the less severe outcomes might also be due to the fact that patients with HS are more likely to have consistent contact with the health care system.
The authors noted several limitations to their study. Among them, it was based on patients from a single health care system, and the investigators did not factor in HS severity due to the minimal availability of severity data.
Nonetheless, the authors said their findings align with other emerging evidence that HS does not appear to confer excess risk in patients with COVID-19.
References
1. De DR, Rick JW, Shih T, Hsiao JL, Hamzavi I, Shi VY. COVID-19 infection in hidradenitis suppurativa patients: a retrospective study. Skin Appendage Disord. 2023;9(3):203-206. doi:10.1159/000529462
2. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases.Risk for COVID-19 infection, hospitalization, and death by race/ethnicity. CDC. Updated May 25, 2023. Accessed July 6, 2023. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
What Mass General Brigham Is Doing to Combat Prostate Cancer Disparities Among Men of Color
May 5th 2024Quoc-Dien Trinh, MD, MBA, chief of urology at Brigham & Women's Faulkner Hospital, highlighted successful efforts to improve prostate cancer care access for underserved communities in Massachusetts.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Health Equity and Access Weekly Roundup: May 4, 2024
May 4th 2024This week, the Center on Health Equity and Access highlights a variety of gaps that exist in health care, spanning women's health, the rising rate of metabolic disease, and policy for LGBTQ+ and immigrant populations. The consensus among featured experts points to comprehensive care models.
Read More
A new federal rule will enable thousands of immigrants in the Deferred Action for Childhood Arrivals (DACA) program to obtain health care through the Affordable Care Act; a forthcoming CMS rule is expected to lower home-based care wait times and raise caregiver wages; the HHS Office for Civil Rights has finalized 2 rules that strengthen the ACA’s health care discrimination ban.
Read More